A study to evaluate the effects of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.

Trial Profile

A study to evaluate the effects of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Interferon alpha-n1 (Primary)
  • Indications Liver cirrhosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top